Product Specifications: Lyophilized Powder (>99% purity) in 3ml vial. *Requires Reconstitution ** Available for bulk custom order with 57 Cap/Crimp colors to choose from.
Application: Research peptide evaluated in obesity and weight loss studies
Chemical Formula: C225H348N48O68
CAS Number: 2023788-19-2
Molecular Weight: ~4813.5 g/mol
Concentration: ≥99%
Tirzepatide functions as a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Research has demonstrated that it primarily stimulates insulin secretion in the human pancreas via the GIP receptor.
Summary of Clinical Benefits
- Weight Management
- Substantial weight reduction (up to 20.9% over 72 weeks)
- Sustained long-term weight loss maintenance
- Metabolic Health
- Improved glycemic control
- Enhanced insulin sensitivity
- Better lipid profiles
- Cardiovascular Protection
- Reduced risk of heart failure progression
- Improved cardiovascular outcomes in obesity patients
- 38-46% reduction in cardiovascular events
- Additional Benefits
- Potential improvement in liver health and fibrosis
- Enhanced kidney function
- Possible benefits for sleep apnea management
Primary Research Applications
1. Obesity Management
Tirzepatide shows remarkable promise in obesity treatment:
- The SURMOUNT-1 trial demonstrated unprecedented weight loss of up to 20.9% over 72 weeks
- Long-term efficacy studies extending to three years will be presented at ECO 2025, focusing on sustained weight management outcomes
- Clinical trials show superior efficacy compared to other treatments, including semaglutide
- High completion rates (81%) in 52-week trials demonstrate strong tolerability
2. Type 2 Diabetes Treatment
Studies demonstrate significant metabolic benefits:
- Substantial improvements in glycemic control through multiple Phase 2 and 3 trials
- Combined benefits of weight reduction and enhanced insulin sensitivity
- Ongoing investigation of long-term metabolic outcomes
3. Cardiovascular and Heart Failure Management
Recent research reveals significant cardiovascular benefits:
- 46% reduction in risk of worsening heart failure and cardiovascular events in patients with obesity and HFpEF
- 38% reduction in cardiovascular death or heart failure worsening compared to placebo
- Improved cardiovascular outcomes in patients with preserved ejection fraction
4. Metabolic Associated Steatohepatitis (MASH/NASH)
Emerging research shows promise in liver disease treatment:
- Superior efficacy compared to placebo for MASH resolution
- More than 50% of patients showed improvement in fibrosis at 52 weeks
- Potential for reducing hepatic inflammation and reversing fibrosis
5. Sleep Disorders
Novel applications in sleep medicine:
- First medication specifically investigated for treating obstructive sleep apnea (OSA)
- Ongoing evaluation for moderate to severe OSA in people with obesity
- Potential improvements in quality of life for OSA patients
6. Chronic Kidney Disease
Emerging research in renal health:
- Improved kidney function in patients with obesity and heart failure
- Investigation of preventive effects against chronic kidney disease progression
Future Research Directions
Current and planned research focuses on:
- Extended long-term safety and efficacy profiles beyond three years
- Optimization of patient selection and treatment strategies
- Comparative effectiveness studies versus existing treatments
- Investigation of novel therapeutic applications in related metabolic conditions
References:
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038
Frías, J. P. (2023). An update on tirzepatide for the management of type 2 diabetes: A focus on the phase 3 clinical development program. Expert Review of Endocrinology & Metabolism, 18(2), 111-130. https://doi.org/10.1080/17446651.2023.2184796
Kushner, P., Anderson, J. E., Simon, J., Boye, K. S., Ranta, K., Torcello-Gómez, A., & Levine, J. A. (2023). Efficacy and safety of tirzepatide in adults with type 2 diabetes: A perspective for primary care providers. Clinical Diabetes, 41(2), 258-272. https://doi.org/10.2337/cd22-0029
Disclaimer: This product is intended solely for laboratory research purposes. It is not suitable for consumption by humans, nor for medical, veterinary, or household purposes. Researchers should handle all peptides with care and adhere to strict safety guidelines during experiments. Only qualified professionals with appropriate expertise should manage and handle this product. The distributor, manufacturer, and seller of this product are not responsible for misuse or any resulting consequences. By accessing this product, you consent to comply with these terms and conditions.
